News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Guidance
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Olema Oncology (Nasdaq: OLMA) has appointed Jason O’Byrne as its new Chief Financial Officer, bringing over two decades of finance leadership experience in the biotech and pharmaceutical sectors. This appointment comes as the company approaches pivotal data from its OPERA-01 study and prepares for …
Olema Pharmaceuticals, Inc. (Olema Oncology) has appointed Jason O’Byrne, MBA, as its new Chief Financial Officer. O'Byrne brings over two decades of finance and operations leadership from high-growth biotechnology and pharmaceutical organizations, including roles at Vir Biotechnology, Caribou Biosciences, Audentes Therapeutics, and Genentech/Roche. His …
Olema Pharmaceuticals' stock fell by 12.90% after the company announced that pivotal breast cancer data for its Phase 3 OPERA-01 trial would be delayed until the first quarter of 2027. Despite this setback, the company presented initial Phase 1 data for OP-3136, showing its …
Citigroup has lowered its price target for Olema Pharmaceuticals (NASDAQ:OLMA) to $59.00 but maintained a "buy" rating, indicating a significant potential upside. This adjustment comes as the company reported a larger-than-expected quarterly loss of $0.61 per share. Olema Pharmaceuticals is a clinical-stage biotech focusing …
Olema Pharmaceuticals (NASDAQ:OLMA) gapped down after reporting Q2 EPS of $(0.61), missing analyst estimates. Despite the disappointing earnings, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and a $43.90 target price. Institutional investors hold a significant portion of the stock, while …
Olema Pharmaceuticals, Inc.'s average 12-month price target has been adjusted to $39.9, down from $40.7, according to estimates from 10 analysts. This new target suggests a potential upside of approximately 234% based on the August 10 closing price. The consensus rating from 11 analysts …
Olema Pharmaceuticals (NASDAQ:OLMA) reported a second-quarter loss of $0.61 per share, missing analyst estimates by $0.06, leading to a 5.8% stock decline. The company's net loss increased to $63.2 million due to higher spending on clinical development for breast cancer therapies palazestrant and OP-3136. …
Olema Oncology announced its financial and operating results for the second quarter of 2026, highlighting the completion of enrollment in its pivotal Phase 3 OPERA-01 trial with top-line data expected in Q1 2027. The company also reported initial Phase 1 clinical data for OP-3136, …
Olema Pharmaceuticals reported a Q2 EPS of $(0.61), missing the analyst consensus of $(0.55) by 10.91%. This represents a 19.61% increase in losses year-over-year from $(0.51), indicating persistent profitability challenges. The company's financial trajectory suggests a disconnect between market expectations and its current performance, …
Olema Pharmaceuticals (OLMA) reported a Q2 loss per share of $0.61, which is wider than the FactSet estimated loss of $0.55 per share. The company is a clinical-stage biopharmaceutical company focused on breast cancer treatments. The article also mentions recent news regarding their clinical …
Olema Pharmaceuticals (NASDAQ:OLMA) reported a quarterly loss of $0.61 per share, missing analysts' consensus estimate by $0.08. The company's stock traded down to $11.94, with a market capitalization of $1.04 billion. Despite missing estimates, Wall Street analysts maintain a "Moderate Buy" consensus rating with …
Olema Pharmaceuticals is set to report its second-quarter results, with analysts expecting wider losses as the clinical-stage biotech continues to advance its breast cancer pipeline. Investors are keenly awaiting top-line data from its Phase 3 OPERA-01 trial, expected this fall, which will be crucial …
Dimensional Fund Advisors LP increased its stake in Olema Pharmaceuticals (NASDAQ:OLMA) by 12.9%, acquiring an additional 123,790 shares to bring its total holding to 1.08 million shares, valued at $16.1 million. Institutional ownership of OLMA remains high at 91.78%, with several other firms also …
FMR LLC and Abigail P. Johnson have disclosed a 13.8% beneficial ownership stake in Olema Pharmaceuticals Inc. (OLMA) through an Amendment No. 2 to a Schedule 13G filing. This represents 12,075,061.72 shares as of June 30, 2026. FMR LLC holds sole voting power over …
Olema Pharmaceuticals, Inc. (Olema Oncology) announced that it granted stock options to seven new employees to purchase an aggregate of 254,540 shares of the Company's common stock. These grants, effective August 3, 2026, were made under Olema's 2022 Inducement Plan as an inducement for …
Olema Pharmaceuticals has seen recent insider selling, including a notable divestment by an Independent Director and a larger sale by the Chief Medical Officer last year. While the CMO's sale was at a higher price than current stock, overall insider ownership is modest at …
Olema Oncology has granted stock options to seven new employees, totaling 254,540 shares, effective August 3, 2026. These inducement grants, approved under Olema's 2022 Inducement Plan and in compliance with Nasdaq Listing Rule 5635(c)(4), have an exercise price of $11.28 per share and a …
Olema Pharmaceuticals (OLMA) is scheduled to release its Q2 2026 earnings before market open on Monday, August 10th, with analysts anticipating a loss of $0.53 per share. The company's stock opened at $11.18, down 2.4%, and currently holds a "Moderate Buy" rating with an …
Defilade Capital Management L.P. has increased its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 21.9%, purchasing an additional 269,902 shares to bring its total to 1.50 million shares valued at approximately $22.4 million. This acquisition makes Olema Pharmaceuticals the 14th largest position in Defilade …
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has received a consensus "Moderate Buy" recommendation from fourteen brokerages, with an average 12-month target price of $44.10. Recent analyst reports show a mix of ratings, including buys, holds, and a "strong sell." The company's stock performance indicates a current …
BlackRock, Inc. has filed an amended Schedule 13G/A disclosing beneficial ownership of 6,244,212 shares of Olema Pharmaceuticals, Inc. common stock, representing 7.1% of the outstanding class as of June 30, 2026. BlackRock reported sole voting power over 6,138,842 shares and sole dispositive power over …
This article provides a company profile for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) on the TradingView platform. It outlines access to financial data, statements, statistics, and other fundamental information for the company. The page focuses on the revenue breakdown and overall financial performance accessible to …
Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon sold 12,500 shares of the company's stock for $144,750, reducing his ownership by 1.72%. The stock has recently traded down to $11.30, significantly below its 12-month high of $36.26, and the company reported a quarterly loss of $0.52 …
This article reports on a Form 4 filing for Olema Pharmaceuticals Inc. for transactions that occurred on July 27. It provides the title of the regulatory filing and indicates that more information can be found on Investing.com. The piece is brief, serving mainly as …
Olema Pharmaceuticals director Cyrus Harmon sold 25,000 shares of company stock for a total of $291,162 over two days in late July 2026. Following these sales, Harmon's direct ownership is 702,770 shares, with an additional 117,028 shares held indirectly. Despite recent analyst buy ratings …
This article provides a detailed cash flow statement for Olema Pharmaceuticals Inc (OLMA), covering quarterly and annual operating, investing, and financing activities. It includes financial figures for net income, changes in working capital, capital expenditures, and free cash flow over several fiscal periods. The …
This article provides a detailed risk assessment for Olema Pharmaceuticals Inc (OLMA), focusing on volatility, financial risk, and investment risk metrics. It presents various performance indicators such as Beta, VaR, Maximum Drawdown, Volatility, and Sharpe Ratio across different timeframes alongside liquidity measures. The data …
This article provides a detailed breakdown of Olema Pharmaceuticals Inc (OLMA) shareholder structure, listing major shareholders and their proportional holdings as of updated dates. It also categorizes shareholders by type and presents institutional shareholding data over several quarters, including changes in shares held and …
Search by ticker symbol or company name and select a result to open its chart.